FORM PTO-1585

RE(



 \mathbf{ET}

U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

1-31-92

Tab settings ⇒⇒⇒▼

100905274 NLY

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof		
 Name of conveying party(ies): Teva Pharmaceutical Industries Ltd. Additional name(s) of conveying parties attached? □ Yes ⋈ No 	Name and address of receiving party(ies) Name: Teva Pharmaceuticals USA, Inc. Street Address: 1515 Delp Drive Kulpsville, Pennsylvania 19443	
3. Nature of conveyance:	Additional name(s) & address(es) attached? □ Yes ☒ No	
4. Application numbers or patent numbers: If this document is being filed together with a new application, the execution date of the application is:		
A. Patent Applications	B. Patent No.(s)	
08/969,863		
Additional Numbers attached? □ Yes ⊠ No		
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 1	
Name: Paul A. Fair Internal Address: KENYON & KENYON	7. Total fee (37 C.F.R. 3.41)	
Street Address: One Broadway City: New York State: New York ZIP: 10004	8. Deposit account number:11-0600	
1998 SBURNS 00000124 110600 08969863 DO NOT USE THIS SPACE		
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.		

OMB No. 0651-0011 (exp. 4/94)

Paul A. Fair (Reg. No. 35,866)
Name of Person Signing

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks Box Assignments Washington DC 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of information Systems, PK2-1000C, Washington D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0605-0011), Washington, D.C. 20503

Signature

39607-1

11/20/ 01 FC:

> PATENT REEL: 9592 FRAME: 0188

Total Number of pages including cover sheet, attachments and document: 2

1662/47501

ASSIGNMENT

WHEREAS TEVA PHARMACEUTICAL INDUSTRIES LTD., having a place of business at 5 Basel Street, P.O. Box 3190, Petah Tiqva 49131, Israel, hereinafter called "Assignor," is the owner of the entire right, title, and interest in and to inventions and discoveries in a PROCESS FOR THE PREPARATION OF TERAZOSIN HYDROCHLORIDE DIHYDRATE (hereinafter, "the Invention"), described in U.S. Patent Application Serial No. 08/969,863, filed on November 14, 1997, and

WHEREAS TEVA PHARMACEUTICALS USA, INC., having a place of business at 1515 Delp Drive, Kulpsville, Pennsylvania, 19443, United States of America, hereinafter called "Assignee," is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, for good and valuable consideration furnished by Assignee, receipt and sufficiency of which is hereby acknowledged, Assignor hereby, without reservations,

- 1. Assigns, transfers, and conveys to Assignee the entire right, title, and interest in and to the Invention in, and only in, the nation and territory of **Barbados**, and in and to any **Barbados** national patent that may issue for the Invention; and
- 2. Authorizes Assignee to file, under the International Convention or otherwise, for patent protection for the Invention within the nation and territory of Barbados.

	TEVA PHARMACEUTICAL INDUSTRIES
(1) Signature:	Helinduh Lunch
Name of Person Signing:	Yehudah Livneh
Title of Person Signing:	Director of Patents
Date:	Oct. 13, 1916
(2) Signature:	M. Man,
Name of Person Signing:	Meron Mann
Title of Person Signing:	corp V-P, Chemicals
Date:	oct, 19, 1998

Signed and sealed this day of ______, 1998.

RECORDED: 11/16/1998

21435-1

PATENT REEL: 9592 FRAME: 0189

LTD.